• Home
  • About
    • Group CEO
    • Management Team
    • Supervisory Board
    • Scientific Advisory Board
    • Affiliates
    • R&D Partnerships
    • Distributors
    • Quality Standards
    • Location
  • Services
    • Proteomics
    • Genomics Transcriptomics
    • Flow Cytometry
    • Assay Development
    • Monoclonal Antibodies
    • Biobanking
    • Custom Kit Production
    • OLINK Services
    • Biomarker Data Analyses
  • R&D
  • Products
    • MEMORYLINC
    • NEUROLINCS
    • FIMICS
    • BIOPRED
    • IVD Products
    • ELISA Kits
    • Recombinant Proteins
    • Monoclonal Abodies
    • Clinical Samples
  • Quality
  • Investors
    • Financial Management
    • Financial Data
    • Shareholders
  • Media
    • Press Releases
    • Media News
    • Newsletters
    • Posts
    • All Media
  • Careers
  • IFU APO-Easy
  • Copy of IFU APO-Easy
  • Stability APO-Easy
  • APO-Easy-FLS-OE02-01
  • APO-Easy-FLS-OE02-02
  • APO-Easy-FLS-OE02-03
Contact
Firalis
  • Home
  • About
  • Services
  • Products
  • R&D
  • Quality
  • Investors
  • Media
COVIRNA Project Final Conference takes place on 19-April-23

COVIRNA Project Final Conference takes place on 19-April-23

After 30 months of collaboration, this Final Conference will present the achievements of the COVIRNA project. We will look at the database built with patients data and share learnings to facilitate the roll out of the RNA-based molecular research methodology in personalised diagnosis and therapy. In addition, the event will offer a platform to discuss what is needed for the product development of the COVIRNA toolkit and how it can be exploited for long-COVID or other (communicable) diseases.

 

The conference will take place in Brussels on Wednesday, 19 April 2023 at 14:00 – 17:30 and will be followed by a cocktail reception. You will have the opportunity to meet and network with the COVIRNA project partners and other industry leaders. For more, visit COVIRNA Project official public website here: https://covirna.eu/

 

About COVIRNA :

At the dawn of the COVID-19 pandemic, the European Commission earmarked a large envelop to develop rapid health-related approaches to respond to it, and to deliver quick results for society for a higher level of preparedness of health systems including medical supplies, equipment, technologies, socio-economic impact analysis of the outbreak.  The COVIRNA project was a response to this objective by developing a CE-marked personalised diagnostic tool allowing the risk stratification of patients who will most likely be subject to fatal cardiovascular complication due to their COVID-19 infection. This novel approach allows health providers to improve clinical decision-making, adapt treatment, inform drug design and enable individualised surveillance, care and follow-up of COVID-19 patients.

 

Firalis has been a pioneering SME taking a key role in the project with its European-leader expertise in biomarker R&D, from discovery to validation and up to clinical qualification.

 

07.04.2023

Contact Firalis

Firalis Group

© Copyright 2020 all rights reserved. 

The company logos, products and service marks are trademarks or registered trademarks of Firalis.

-----------------------------------------------------------------------------------------------------------------------

Information addressed to health professionals. The products presented on this site are for professional use only and, where applicable, comply with the requirements of the IVD Directive 98/79 / EC. Instructions for use must be consulted before using these products.

-----------------------------------------------------------------------------------------------------------------------

Headquarter : 17 Rue du Fort 68330 Huningue FRANCE